Screener
Inhibikase Therapeutics, Inc. IKT Q2 2026 earnings
Reported August 11, 2026 · After market close
EPS-$0.11Miss by $0.00
EPS estimate-$0.11
Next report
Nov 13, 2026 (in 2 months)EPS estimate-$0.11
Versus estimates
Diluted EPS
FAQ
- When did Inhibikase Therapeutics, Inc. report Q2 2026 earnings?
- Inhibikase Therapeutics, Inc. (IKT) reported Q2 2026 earnings on August 11, 2026 after market close.
- What were Inhibikase Therapeutics, Inc.'s Q2 2026 revenue and EPS?
- Inhibikase Therapeutics, Inc. reported eps of $-0.11 for Q2 2026.
- Did Inhibikase Therapeutics, Inc. beat estimates in Q2 2026?
- EPS missed the consensus estimate of $-0.11 by $0.00.
- How did Inhibikase Therapeutics, Inc.'s Q2 2026 results compare year-over-year?
- Compared to the same quarter a year prior, eps grew 0.0% from $-0.11.
- Where can I find Inhibikase Therapeutics, Inc.'s Q2 2026 SEC filings?
- You can read the 8-K earnings release (0001193125-26-344623) and the 10-Q periodic report (0001193125-26-344707) directly on SEC EDGAR. The filing index links above go to sec.gov.
